Display options
Cite
Bassetti M, Vena A, Giacobbe DR, et al. Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing . Open Forum Infect Dis. 2020;7(5):ofaa139doi: 10.1093/ofid/ofaa139.
Bassetti, M., Vena, A., Giacobbe, D. R., Falcone, M., Tiseo, G., Giannella, M., Pascale, R., Meschiari, M., Digaetano, M., Oliva, A., Rovelli, C., Carannante, N., Losito, A. R., Carbonara, S., Mariani, M. F., Mastroianni, A., Angarano, G., Tumbarello, M., Tascini, C., Grossi, P., Mastroianni, C. M., Mussini, C., Viale, P., Menichetti, F., Viscoli, C., Russo, A. (2020). Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing . Open forum infectious diseases, 7(5), ofaa139. https://doi.org/10.1093/ofid/ofaa139
Bassetti, Matteo, et al. "Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing ." Open forum infectious diseases vol. 7,5 (2020): ofaa139. doi: https://doi.org/10.1093/ofid/ofaa139
Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, Pascale R, Meschiari M, Digaetano M, Oliva A, Rovelli C, Carannante N, Losito AR, Carbonara S, Mariani MF, Mastroianni A, Angarano G, Tumbarello M, Tascini C, Grossi P, Mastroianni CM, Mussini C, Viale P, Menichetti F, Viscoli C, Russo A. Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing . Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139. doi: 10.1093/ofid/ofaa139. eCollection 2020 May. PMID: 32462046; PMCID: PMC7237821.
Copy Download .nbib Format: NLM
Share it on

Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139. doi: 10.1093/ofid/ofaa139. eCollection 2020 May.

Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing .

Open forum infectious diseases

Matteo Bassetti, Antonio Vena, Daniele Roberto Giacobbe, Marco Falcone, Giusy Tiseo, Maddalena Giannella, Renato Pascale, Marianna Meschiari, Margherita Digaetano, Alessandra Oliva, Cristina Rovelli, Novella Carannante, Angela Raffaella Losito, Sergio Carbonara, Michele Fabiano Mariani, Antonio Mastroianni, Gioacchino Angarano, Mario Tumbarello, Carlo Tascini, Paolo Grossi, Claudio Maria Mastroianni, Cristina Mussini, Pierluigi Viale, Francesco Menichetti, Claudio Viscoli, Alessandro Russo,

Affiliations

  1. Department of Health Sciences, University of Genoa, Genoa, Italy.
  2. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  3. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  4. Infectious Diseases Clinic, University of Modena and Reggio Emilia, Modena, Italy.
  5. Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, Rome, Italy.
  6. IRCCS Neuromed, Pozzilli, Isernia, Italy.
  7. Department of Infectious and Tropical Diseases, University of Insubria, Ospedale di Circolo-Fondazioni Macchi, Varese, Italy.
  8. First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, Naples, Italy.
  9. UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  10. Clinic of Infectious Diseases, University of Bari, Bari, Italy.
  11. Infectious Diseases Unit, 'Annunziata' Hospital, Cosenza, Italy.
  12. UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.

PMID: 32462046 PMCID: PMC7237821 DOI: 10.1093/ofid/ofaa139

Abstract

BACKGROUND: Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing

METHODS: A multicenter retrospective study was performed in Italy (June 2016-June 2019). Successful clinical outcome was defined as complete resolution of clinical signs/symptoms related to ESBL-E infection and lack of microbiological evidence of infection. The primary end point was to identify predictors of clinical failure of C/T therapy.

RESULTS: C/T treatment was documented in 153 patients: pneumonia was the most common diagnosis (n = 46, 30%), followed by 34 cases of complicated urinary tract infections (22.2%). Septic shock was observed in 42 (27.5%) patients. C/T was used as empiric therapy in 46 (30%) patients and as monotherapy in 127 (83%) patients. Favorable clinical outcome was observed in 128 (83.7%) patients; 25 patients were considered to have failed C/T therapy. Overall, 30-day mortality was reported for 15 (9.8%) patients. At multivariate analysis, Charlson comorbidity index >4 (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.9-3.5;

CONCLUSIONS: Data show that C/T could be a valid option in empiric and/or targeted therapy in patients with severe infections caused by ESBL-producing

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Keywords: CRRT; ESBL; Enterobacterales; ceftolozane/tazobactam; septic shock

References

  1. JAMA. 2016 Feb 23;315(8):801-10 - PubMed
  2. Lancet. 2015 May 16;385(9981):1949-56 - PubMed
  3. Int J Antimicrob Agents. 2018 Mar;51(3):443-449 - PubMed
  4. Clin Microbiol Infect. 2014 Dec;20(12):1357-62 - PubMed
  5. Clin Infect Dis. 2015 May 15;60(10):1462-71 - PubMed
  6. Antimicrob Agents Chemother. 2005 Feb;49(2):760-6 - PubMed
  7. Clin Infect Dis. 2017 Jul 1;65(1):158-161 - PubMed
  8. JAMA. 2018 Sep 11;320(10):984-994 - PubMed
  9. Int J Antimicrob Agents. 2019 Apr;53(4):408-415 - PubMed
  10. J Antimicrob Chemother. 2004 Jul;54(1):134-8 - PubMed
  11. Lancet. 2000 Oct 7;356(9237):1255-9 - PubMed
  12. J Antimicrob Chemother. 2017 Jan;72(1):268-272 - PubMed
  13. Pharmacotherapy. 2016 May;36(5):e30-e33 - PubMed
  14. Antimicrob Agents Chemother. 2007 Jun;51(6):1987-94 - PubMed
  15. Clin Infect Dis. 2006 Dec 1;43(11):1407-14 - PubMed
  16. Int J Antimicrob Agents. 2018 Nov;52(5):577-585 - PubMed
  17. Clin Infect Dis. 2017 Jul 1;65(1):110-120 - PubMed
  18. Clin Infect Dis. 2015 May 1;60(9):1319-25 - PubMed
  19. Lancet Infect Dis. 2008 Mar;8(3):159-66 - PubMed
  20. Expert Rev Anti Infect Ther. 2018 Apr;16(4):307-320 - PubMed
  21. Clin Microbiol Rev. 2005 Oct;18(4):657-86 - PubMed
  22. J Antimicrob Chemother. 2017 May 1;72(5):1386-1395 - PubMed
  23. Int J Antimicrob Agents. 2017 May;49(5):624-630 - PubMed
  24. Lancet Infect Dis. 2019 Dec;19(12):1299-1311 - PubMed
  25. Int J Antimicrob Agents. 2016 Sep;48(3):342-3 - PubMed
  26. Int J Antimicrob Agents. 2016 Dec;48(6):748-752 - PubMed

Publication Types